Display options
Cite
Ito F, Ito T. High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease. Antioxidants (Basel). 2020;9(5)doi: 10.3390/antiox9050362.
Ito, F., & Ito, T. (2020). High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease. Antioxidants (Basel, Switzerland), 9(5), . https://doi.org/10.3390/antiox9050362
Ito, Fumiaki, and Ito, Tomoyuki. "High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease." Antioxidants (Basel, Switzerland) vol. 9,5 (2020). doi: https://doi.org/10.3390/antiox9050362
Ito F, Ito T. High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease. Antioxidants (Basel). 2020 Apr 26;9(5). doi: 10.3390/antiox9050362. PMID: 32357465; PMCID: PMC7278571.
Copy Download .nbib Format: NLM
Share it on

Antioxidants (Basel). 2020 Apr 26;9(5). doi: 10.3390/antiox9050362.

High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease.

Antioxidants (Basel, Switzerland)

Fumiaki Ito, Tomoyuki Ito

Affiliations

  1. The Institute of Prophylactic Pharmacology, Shinagawa, Tokyo 140-0001, Japan.
  2. Physical Medicine and Rehabilitation, Tanabe Memorial Hospital, Kyotanabe-City, Kyoto 610-0331, Japan.
  3. Department of Rehabilitation Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.

PMID: 32357465 PMCID: PMC7278571 DOI: 10.3390/antiox9050362

Abstract

Lipid markers are well-established predictors of vascular disease. The most frequently measured lipid markers are total cholesterol, high-density lipoprotein (HDL)-cholesterol (HDL-C), LDL cholesterol (LDL-C), and triglyceride. HDL reduces atherosclerosis by multiple mechanisms, leading to a reduced risk of cardiovascular disease, and HDL-C, as a metric of HDL quantity, is inversely associated with cardiovascular disease, independent of LDL-C. However, the quality of the HDL appears to be more important than its quantity, because HDL loses its antiatherogenic functions due to changes in its composition and becomes "dysfunctional HDL". Although there is evidence of the existence of "dysfunctional HDL", biomarkers for monitoring dysfunctional HDL in clinical practice have not yet been established. In this review, we propose a new lipid panel for the assessment of dysfunctional HDL and lipoprotein-related atherosclerotic cardiovascular disease. The lipid panel includes the measurement of lipid peroxide and triglyceride contents within HDL particles.

Keywords: atherosclerosis; cardiovascular disease; chronic inflammation; high-density lipoproteins; low-density lipoproteins; reactive oxygen species and lipid peroxidation; triglycerides

References

  1. Antioxidants (Basel). 2019 Mar 25;8(3): - PubMed
  2. Circulation. 2007 Jan 30;115(4):450-8 - PubMed
  3. FEBS Lett. 1998 Jan 16;421(3):180-4 - PubMed
  4. Curr Mol Pharmacol. 2020 Mar 20;: - PubMed
  5. Front Physiol. 2013 Sep 04;4:242 - PubMed
  6. J Hum Hypertens. 2008 Jan;22(1):24-31 - PubMed
  7. J Photochem Photobiol B. 2010 Dec 2;101(3):251-64 - PubMed
  8. Eur Heart J. 2017 Aug 21;38(32):2459-2472 - PubMed
  9. JCI Insight. 2020 Jan 16;5(1): - PubMed
  10. J Atheroscler Thromb. 2019 Nov 1;26(11):945-946 - PubMed
  11. Biochem J. 1996 Mar 15;314 ( Pt 3):739-42 - PubMed
  12. Atherosclerosis. 2019 Jan;280:7-13 - PubMed
  13. J Lipid Res. 2013 Dec;54(12):3227-43 - PubMed
  14. Lipids Health Dis. 2018 May 29;17(1):130 - PubMed
  15. Int J Mol Sci. 2019 Jun 27;20(13): - PubMed
  16. Free Radic Biol Med. 2013 Jun;59:85-91 - PubMed
  17. Biochem Biophys Res Commun. 2005 Dec 9;338(1):668-76 - PubMed
  18. Mol Cell Biochem. 2018 Mar;440(1-2):167-187 - PubMed
  19. Arch Intern Med. 2001 Jun 11;161(11):1413-9 - PubMed
  20. Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2169-75 - PubMed
  21. J Biol Chem. 2005 Oct 28;280(43):36386-96 - PubMed
  22. Cell Res. 2006 Oct;16(10):799-808 - PubMed
  23. J Biol Chem. 1983 Oct 10;258(19):11751-7 - PubMed
  24. Circ Res. 2017 Feb 17;120(4):713-735 - PubMed
  25. Chem Phys Lipids. 2009 Jan;157(1):1-11 - PubMed
  26. Curr Med Chem. 2019;26(9):1576-1593 - PubMed
  27. Cell Physiol Biochem. 2014;34(1):172-84 - PubMed
  28. Lancet. 2014 Aug 16;384(9943):618-625 - PubMed
  29. Cell. 2015 Mar 26;161(1):161-172 - PubMed
  30. Nat Med. 2014 Feb;20(2):193-203 - PubMed
  31. Nat Rev Cardiol. 2016 Jan;13(1):48-60 - PubMed
  32. PLoS One. 2015 Apr 07;10(4):e0123138 - PubMed
  33. J Am Coll Cardiol. 2018 Feb 13;71(6):620-632 - PubMed
  34. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10316-20 - PubMed
  35. Circulation. 2011 May 24;123(20):2292-333 - PubMed
  36. Circulation. 2005 Nov 29;112(22):3375-83 - PubMed
  37. Handb Exp Pharmacol. 2015;224:207-28 - PubMed
  38. Handb Exp Pharmacol. 2015;224:337-66 - PubMed
  39. Front Pharmacol. 2015 Oct 05;6:218 - PubMed
  40. Int J Mol Sci. 2017 Feb 21;18(2): - PubMed
  41. J Biol Chem. 2014 Apr 11;289(15):10276-92 - PubMed
  42. J Cardiol. 2014 Jan;63(1):60-8 - PubMed
  43. Cholesterol. 2014;2014:109263 - PubMed
  44. J Res Health Sci. 2019 May 13;19(2):e00442 - PubMed
  45. Sci Rep. 2016 Jan 18;6:19249 - PubMed
  46. Circulation. 2010 Jan 5;121(1):110-22 - PubMed
  47. Biochem Soc Trans. 2003 Oct;31(Pt 5):1066-9 - PubMed
  48. Lipids Health Dis. 2016 Jun 07;15:104 - PubMed

Publication Types

Grant support